Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients

Wanaporn Charoenchokthavee1 Department of Pharmacy Practice, Faculty of Pharmaceutical Science, Chulalongkorn UniversityCorrespondence[email protected]

Nutthada Areepium2 Medical Oncology Unit, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Pathumwan, Bangkok, Thailand

Duangchit Panomvana2 Medical Oncology Unit, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Pathumwan, Bangkok, Thailand

Virote Sriuranpong2 Medical Oncology Unit, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Pathumwan, Bangkok, Thailand

Pages 249-256 | Published online: 15 Apr 2017

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

KleinDJThornCFDestaZFlockhartDAAltmanRBKleinTEPharmGKB summary: tamoxifen pathway, pharmacokineticsPhar-macogenet Genomics20132311643647
PubMed Web of Science ®Google Scholar
SaladoresPHPrechtJCSchrothWBrauchHSchwabMImpact of metabolizing enzymes on drug response of endocrine therapy in breast cancerExpert Rev Mol Diagn201313434936523638818
PubMed Web of Science ®Google Scholar
RaeJMDrurySHayesDFCYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patientsJ Natl Cancer Inst2012104645246022395643
PubMed Web of Science ®Google Scholar
KarleJBolbrinkerJVoglSInfluence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancerBreast Cancer Res Treat2013139255356023686417
PubMed Web of Science ®Google Scholar
ReganMMLeyland-JonesBBouzykMCYP2D6 Genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1–98 trialJ Natl Cancer Inst2012104644145122395644
PubMed Web of Science ®Google Scholar
WestbrookKStearnsVPharmacogenomics of breast cancer therapy: an updatePharmacol Ther2013139111123500718
PubMed Web of Science ®Google Scholar
BinkhorstLMathijssenRHJGhobadi Moghaddam-HelmantelIMQuantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometryJ Pharm Biomed Anal20115651016102321872414
PubMed Web of Science ®Google Scholar
KiyotaniKMushirodaTNakamuraYZembutsuHPharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transportersDrug Metab Pharmacokinet201227112213122041137
PubMed Web of Science ®Google Scholar
MürdterTESchrothWBacchus-GerybadzeLActivity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasmaClin Pharmacol Ther2011895110
Web of Science ®Google Scholar
BarginearMFJaremkoMPeterIIncreasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity scoreClin Pharmacol Ther201190460561121900890
PubMed Web of Science ®Google Scholar
Zafra-CeresMde HaroTFarez-VidalEInfluence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancerInt J Med Sci201310793293723781139
PubMed Web of Science ®Google Scholar
RatainMJNakamuraYCoxNJCYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological qualityClin Pharmacol Ther201394218518723872831
PubMed Web of Science ®Google Scholar
HertzDLMcLeodHLIrvin JrWJTamoxifen and CYP2D6: a contradiction of dataOncologist201217562063022531359
PubMed Web of Science ®Google Scholar
TehLKBertilssonLPharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importanceDrug Metab Pharmacokinet2012271556722185816
PubMed Web of Science ®Google Scholar
Fernández-SantanderAGaibarMNovilloARelationship between genotypes Sult1a2 and Cyp2d6 and tamoxifen metabolism in breast cancer patientsPLoS One201387e7018323922954
PubMed Web of Science ®Google Scholar
LimJSChenXASinghOImpact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patientsBr J Clin Pharmacol201171573775021480951
PubMed Web of Science ®Google Scholar
ChamnanphonMPechatananKSirachainanEAssociation of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifenPharmacogenomics Pers Med2013613748
Google Scholar
CharoenchokthaveeWPanomvanaDSriuranpongVAreepiumNPrevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatmentBreast Cancer (Dove Med Press)2016814915527540311
PubMedGoogle Scholar
AreepiumNPanomvanaDRungwanonchaiPSathapornSVoravudNEffects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patientsBreast Cancer (Dove Med Press)20135737824648760
PubMedGoogle Scholar
CharoenchokthaveeWAyudhyaDPSriuranpongVAreepiumNEffects of SULT1A1 copy number variation on estrogen concentration and tamoxifen-associated adverse drug reactions in premenopausal Thai breast cancer patients: a preliminary studyAsian Pac J Cancer Prev20161741851185527221864
PubMedGoogle Scholar
FaulFErdfelderELangA-GBuchnerAG*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciencesBehav Res Methods200739217519117695343
PubMed Web of Science ®Google Scholar
Cohen Jacob Statistical Power Analysis for the Behavioral Sciences2nd edHillsdale, NJLawrence Erlbaum Associates1988
Google Scholar
ZhuYBZhangQZouJJYuCXXiaoDWOptimizing high-performance liquid chromatography method with fluorescence detection for quantification of tamoxifen and two metabolites in human plasma: application to a clinical studyJ Pharm Biomed Anal200846234935518037598
PubMed Web of Science ®Google Scholar
KirkREExperimental Design: Procedures for the Behavioral Sciences4th edThousand Oaks, CASAGE2013
Google Scholar
SaladoresPMurdterTEcclesDTamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancerPharmacogenomics J2014151849425091503
PubMed Web of Science ®Google Scholar
LienEASøilandHLundgrenSSerum concentrations of tamoxifen and its metabolites increase with age during steady-state treatmentBreast Cancer Res Treat2013141224324823996142
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date